Elevidys

Product

Last mentioned: Mar 25, 2026

Timeline

  1. Options Surge

    Traders purchase large volume of call options following clinical data reports.

  2. Clinical Data Release

    Early data for RNA therapies in FSHD and DM1 shows promise.

  3. Regulatory Strategy

    Sarepta announces plan to seek full FDA approval for exon-skipping drugs.

  4. Analyst Revisions

    Multiple brokerages raise price targets for SRPT stock.

  5. SEC Filing

    Company files 8-K regarding changes in director and officer elections.

Stories mentioning Elevidys 1

pharma Neutral

Sarepta Therapeutics Sees Surge in Call Options Following Rare Disease Data

Bullish options activity for Sarepta Therapeutics (SRPT) spiked on March 25, 2026, as the market reacted to promising early data for its RNA-based rare disease pipeline. The increased trading volume coincides with the company’s strategic push for full FDA approval of its core Duchenne muscular dystrophy portfolio.

2 sources